Global E-Health Forum - Hamburg 2011

11 - 13 October 2011, Hamburg, Germany.
Improving the quality of healthcare, increasing the efficiency of the systems and ensuring patient empowerment - these are the common goals worldwide when discussing the necessary transformation of the systems in order to guarantee a sustainable healthcare delivery in the future. The Global E-Health Forum - Hamburg 2011 will represent major stakeholders involved in designing personalized healthcare.

"E-Health is increasingly seen as a key enabler for this transformation," so Ljubisav Matejevic, founder and honorary chairman of the Global E-Health Forum. "And as a key enabler for the evolution process towards personalized healthcare. Healthcare that is proactive, instead of reactive, gives the patients the opportunity and the responsibility to become more involved in their own health. The ultimate goal will be to shape preventive and diagnostic care to match each person's unique characteristics."

The initiators of the Global E-Health Forum - Hamburg Chamber of Commerce, IBM and ICC - have developed this platform to discuss e-health strategies, best practices and new services/patient-centric approaches in a global context. While the main target groups consist of CEOs, CIOs and CFOs of hospitals and clinics, the comprehensive program will also attract representatives from governmental bodies, health insurance organizations, service providers, influencers from hospital and health management associations as well as representatives from universities/research institutes. Canada supports the Global E-Health Forum - Hamburg 2011 as partner country.

The first two conference days will feature speakers from all over the globe:

  • Richard C. Alvarez, President and Chief Executive Officer of Canada Health Infoway, with "Transforming Healthcare in Canada through E-Health"
  • Prof. WEN Ze Huai, (M. D.), Key Unit of Methodology in Clinical Research, Guangdong Traditional Chinese Medicine International Clinical Research Center, Research Center Guangdong Academy of Chinese Medical Sciences, with "Designing Personalized Healthcare for Integrated Medicine by Using Information Technology"
  • Dr. Eric M. Liederman, Director of Medical Informatics, The 45 Permanente Medical Group (USA), with "Balancing Privacy Protection with Patient Care"
  • Prof. Dr. Roland Eils, Division Head "Theoretical Bioinformatics", German Cancer Research Center (DKFZ) and Manuela Mueller-Gerndt, Healthcare Leader, IMT Germany, Smarter Healthcare, IBM Deutschland GmbH with "Oncology as a Key Driver for Cancer Research and Individualized Medicine"
  • Chai Chuah, National Director, National Health Board Business Unit, New Zealand Ministry of Health, with "Sustainable Personalized Healthcare - Challenges and Opportunities"

Their strategy presentations and case studies will be complemented by discussion forums, workshops and an exhibition of solution providers. During the evening reception at the U.S. Consulate General on October 11, there will be manifold opportunity of knowledge and experience exchange as well as networking. The third day is dedicated to various breakout sessions and guided tours at different locations (among others hospitals) targeting the individual information needs of special interest groups. The third day is dedicated to guided tours of different hospitals and clinics in Hamburg, three of them being Asklepios clinics. The Asklepios Hospital Group renewed its cooperation partnership with the Global E-Health Forum.

For further information and registration, please visit:
http://www.global-ehealth-forum.com

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...